GOLGA6B Inhibitors
GOLGA6B inhibitors encompass a range of chemical compounds that indirectly impact the functional activity of the Golgi apparatus-associated protein GOLGA6B by targeting various cellular mechanisms integral to its operation. Wortmannin, by inhibiting phosphoinositide 3-kinases, impedes vesicular formation and trafficking, thus affecting GOLGA6B's role in these processes. Similarly, Dynasore hampers endocytic pathways by its action on dynamin, a GTPase, which can result in reduced efficiency of Golgi apparatus functions and indirectly decrease GOLGA6B activity. Brefeldin A and Golgicide A target ADP-ribosylation factors and Golgi BFA resistance factor 1, respectively, leading to compromised Golgi structure and function, thereby attenuating GOLGA6B's involvement in Golgi-dependent processes. Monensin and Tunicamycin disrupt the Golgi's pH and cation gradients and inhibit N-linked glycosylation, respectively, causing misfolding of glycoproteins and ensuing Golgi dysfunction, which can diminish GOLGA6B's functional activity.
Additionally, the integrity of the Golgi apparatus and its associated trafficking capabilities, which GOLGA6B is a part of, can be affected by agents that alter the cytoskeleton. Nocodazole and Paclitaxel, by affecting microtubule dynamics-either through depolymerization or stabilization-can lead to altered Golgi-dependent processes. Cytochalasin D's inhibition of actin polymerization disrupts the actin cytoskeleton, further impacting Golgi structure and indirectly GOLGA6B's function. Neomycin, through its binding to phosphoinositides and inhibition of phospholipase C, affects phosphoinositide metabolism critical for membrane trafficking, thereby affecting GOLGA6B's role. Lastly, Deoxynojirimycin and Swainsonine, by targeting glycosidase enzymes and alpha-mannosidase II, interfere with glycoprotein maturation within the Golgi, which is essential for maintaining normal Golgi function and, consequently, GOLGA6B's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3Ks). GOLGA6B is involved in membrane trafficking and PI3Ks are crucial for vesicular formation and trafficking. Therefore, Wortmannin, by inhibiting PI3K, indirectly impedes the trafficking functions that GOLGA6B may be involved in. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
A non-competitive inhibitor of dynamin, a GTPase. Since GOLGA6B is associated with the Golgi apparatus and dynamin is implicated in membrane scission during vesicle trafficking, Dynasore can impede the endocytic pathways, indirectly affecting the Golgi apparatus functions related to GOLGA6B. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (Arf), which disrupts the structure and function of the Golgi apparatus. Brefeldin A, therefore, can affect the processes that GOLGA6B is associated with by disrupting the integrity and function of the Golgi apparatus, indirectly leading to GOLGA6B functional inhibition. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
A monovalent cation ionophore that disrupts Golgi function by altering pH and cation gradients. As GOLGA6B is involved in Golgi function, Monensin can indirectly lead to a decrease in GOLGA6B functional activity by disrupting the Golgi apparatus where GOLGA6B operates. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An inhibitor of N-linked glycosylation. By inhibiting this process, Tunicamycin can disrupt proper folding and function of glycoproteins in the Golgi, indirectly affecting GOLGA6B’s role in the Golgi apparatus due to misfolded glycoproteins accumulating and potentially disrupting Golgi function. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Specifically inhibits Golgi BFA resistance factor 1 (GBF1), a GEF for Arf. By inhibiting GBF1, Golgicide A can disrupt Arf-mediated recruitment of coat proteins to Golgi membranes, indirectly affecting GOLGA6B’s function by altering Golgi membrane dynamics and trafficking pathways. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
A microtubule depolymerizer. As microtubule dynamics are critical for Golgi assembly and positioning, Nocodazole can indirectly affect GOLGA6B’s function by disrupting the microtubule network essential for Golgi apparatus function, potentially leading to altered Golgi-dependent processes in which GOLGA6B is implicated. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
An inhibitor of actin polymerization. Because actin plays a role in maintaining Golgi architecture and vesicle trafficking, Cytochalasin D can indirectly impact GOLGA6B by disrupting the actin cytoskeleton, which is necessary for the maintenance of Golgi structure and function. | ||||||
Neomycin sulfate | 1405-10-3 | sc-3573 sc-3573A | 1 g 5 g | $26.00 $34.00 | 20 | |
An aminoglycoside antibiotic that binds phosphoinositides and can inhibit phospholipase C. Given that GOLGA6B is involved in membrane trafficking, Neomycin may indirectly inhibit GOLGA6B function by altering phosphoinositide metabolism and signaling, which is important for membrane trafficking processes. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
A microtubule stabilizer. While it is known to stabilize microtubules, Paclitaxel can disrupt normal microtubule dynamics, indirectly affecting GOLGA6B by disrupting the microtubule network that is vital for Golgi function and vesicular trafficking processes in which GOLGA6B is involved. | ||||||